For laboratory investigators seeking to source high-purity reagents, 'kopen follistatin peptide' refers to procuring authentic, analytical-grade follistatin proteins for in vitro and preclinical research. Follistatin acts as an endogenous antagonist of activin A and myostatin, serving as a critical tool in cellular differentiation, muscle biology, and TGF-β superfamily signaling assays.
For laboratory investigators seeking to source high-purity reagents, 'kopen follistatin peptide' refers to procuring authentic, analytical-grade follistatin proteins for in vitro and preclinical research. Follistatin acts as an endogenous antagonist of activin A and myostatin, serving as a critical tool in cellular differentiation, muscle biology, and TGF-β superfamily signaling assays.
Researchers searching for 'kopen follistatin peptide' (an international terminology query for procuring follistatin reagents) require validated biochemical purity, verified sequence integrity, and comprehensive analytical documentation. Follistatin is a monomeric autocrine glycoprotein expressed across diverse eukaryotic tissues, primarily investigated for its capacity to bind and neutralize specific members of the transforming growth factor-beta (TGF-β) superfamily.
When obtaining reagents for specialized benchwork, investigators must distinguish between crude peptide mixtures and high-grade recombinants. Sourcing from accredited facilities ensures that experimental assays measuring receptor binding affinity, cell proliferation, or gene expression yield reproducible, statistically sound data without interference from endotoxins or residual synthesis side-products. To review our complete catalog of analytical reagents, visit our all research peptides section.
Follistatin (FST) exists in multiple distinct isoforms resulting from alternative mRNA splicing and post-translational proteolysis. The primary precursor transcript yields two major translation products: Follistatin-317 and Follistatin-344. Proteolytic processing of the C-terminal domain of FST-344 generates the circulating FST-315 isoform, whereas FST-288 represents a shorter, domain-truncated variant with high heparin-binding affinity.
In vitro structural analysis indicates that the follistatin monomer consists of an N-terminal domain followed by three conserved follistatin domains (FS1, FS2, and FS3). Each domain contains a high density of cysteine residues, forming intradomain disulfide bonds essential for tertiary structure stability. The N-terminal domain, along with the FS1 and FS2 regions, forms a high-affinity binding pocket that engulfs the signaling surfaces of target growth factors, effectively blocking their interaction with type I and type II serine/threonine kinase receptors.
The primary biochemical function of follistatin is the high-affinity neutralization of activin A and myostatin (growth differentiation factor 8, or GDF-8). In vitro binding assays demonstrate that one follistatin molecule binds to each subunit of the homodimeric activin A or myostatin protein, creating a 2:1 stoichiometry complex. This stoichiometric encapsulation physically hides the receptor-binding epitopes required to engage the Activin Type II receptor (ActRIIA/ActRIIB) complex.
By preventing ligand-receptor engagement, follistatin suppresses downstream intracellular signaling cascades mediated by Smad2 and Smad3 phosphorylation. In cellular assays, inhibition of Smad2/3 activation downregulates transcriptional targets that normally promote muscle protein degradation or suppress myoblast proliferation. Researchers studying these pathways can explore related compounds through our dedicated myostatin inhibitor mechanisms technical overview.
Preclinical studies in rodent models and immortalized cell lines have documented significant alterations in myogenesis upon exposure to exogenous follistatin recombinant proteins. In vitro myoblast cultures (such as C2C12 cell lines) exposed to follistatin exhibit accelerated myotube fusion, increased expression of myogenin and MyoD, and elevated rates of protein synthesis relative to control cultures.
In vivo rodent models evaluating transgenic overexpression or systemic administration of follistatin demonstrate marked increases in skeletal muscle mass, driven by a combination of muscle fiber hypertrophy and hyperplasia. These phenotypic shifts are attributed to the concurrent blockade of both myostatin and activin A, which otherwise act as negative regulators of muscle tissue growth. Advanced research regarding peptide interactions in metabolic and tissue models is documented in the PX1 Research Library.
When designing preclinical experiments, researchers often evaluate follistatin alongside other regulators of tissue growth and cellular regeneration. Understanding the structural and mechanistic differences between these compounds is critical for selecting the appropriate tool for specific assay parameters.
Compared to broad-spectrum myostatin inhibitors like Ace-031 (a soluble ActRIIB fusion protein), the Follistatin-344 research peptide exhibits target selectivity influenced by its specific domain interaction profile. While Ace-031 sequesters a wider array of ActRIIB ligands (including BMP-9 and BMP-10), follistatin primarily targets activin A, myostatin, and GDF-11. In contrast, non-TGF-β regulatory compounds such as the BPC-157 peptide or cell-signaling agents like IGF-1 LR3 peptide operate through entirely distinct receptor tyrosine kinase and cytoprotective pathways. Researchers comparing these classes should account for these mechanistic distinctions in experimental design.
When purchasing or inquiring to 'kopen follistatin peptide' online, verifying vendor analytical rigorousness is mandatory to preserve experimental integrity. Authentic research peptides must undergo dual-stage analytical validation consisting of Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS).
RP-HPLC establishes the chemical purity percentage by measuring chromatographic peak area, where a threshold of ≥98% purity is the standard for quantitative laboratory investigation. Mass spectrometry confirms the exact molecular weight and amino acid sequence against theoretical values, identifying any truncation or incorrect disulfide coupling. Furthermore, because follistatin assays frequently involve cell culture models, endotoxin testing (typically via Chromogenic LAL assay) must confirm endotoxin levels below 0.01 EU/μg to prevent non-specific inflammatory responses or cell death during in vitro studies.
PX1 Research maintains rigorous quality control frameworks tailored to academic, clinical, and industrial research laboratories. Every batch of follistatin peptide supplied by PX1 Research is manufactured within GMP-compliant facilities located in the United States and subject to independent third-party testing by ISO 17025 accredited analytical laboratories.
Each order includes a lot-specific Certificate of Analysis (COA) detailing full HPLC chromatograms, mass spectrum outputs, purity percentages, and endotoxin metrics. PX1 Research enforces strict lot traceability, ensuring that every vial delivered to your facility matches the exact analytical profile documented in our verification system. Laboratories requiring large quantities for ongoing protocols can establish a dedicated wholesale lab account for streamlined procurement.
Lyophilized follistatin requires careful reconstitution to maintain tertiary protein folding and biological activity. Reconstitution should be performed using sterile, endotoxin-free water or phosphate-buffered saline (PBS, pH 7.4). For long-term storage of reconstituted stock solutions, the addition of a carrier protein (such as 0.1% Bovine Serum Albumin or Human Serum Albumin) is recommended to prevent non-specific adsorption of the peptide to plastic microcentrifuge tubes.
Vials should be allowed to equilibrate to room temperature prior to reconstitution. Solvent should be added gently along the inner wall of the vial, followed by mild swirl agitation. Vortexing or aggressive mechanical agitation must be avoided, as shear forces can disrupt disulfide bonds and precipitate hydrophobic protein domains. Detailed handling parameters for peptide handling can be explored in our growth factor research peptides operational guides.
Lyophilized follistatin peptides are stable at room temperature for brief periods during transit, but long-term storage requires controlled thermal conditions. Upon receipt, unopened vials of lyophilized powder should be stored at -20°C or -80°C in a manual defrost freezer away from light and moisture.
Once reconstituted into aqueous liquid stocks, follistatin solutions should be divided into single-use research aliquots to avoid repeated freeze-thaw cycles, which degrade protein stability through ice crystal formation. Reconstituted aliquots stored at 4°C remain stable for up to 7–14 days when formulated with sterile carrier protein, whereas frozen aliquots stored at -80°C maintain structural stability for up to 6–12 months.
PX1 Research processes and dispatches all orders directly from centralized inventory facilities in California and Arizona. Standard laboratory orders placed Monday through Friday prior to cutoff times ship the same day via climate-conscious express logistics.
This domestic fulfillment infrastructure ensures short transit times, reducing environmental exposure during transport and preserving peptide stability. International research teams inquiring about 'kopen follistatin peptide' receive tracked shipments backed by full customs compliance documentation and temperature-controlled packaging options.
What does 'kopen follistatin peptide' mean in the research market?
The term 'kopen follistatin peptide' originates from Dutch and European research queries meaning 'to buy follistatin peptide'. In laboratory settings, it refers to procuring high-purity, analytical-grade follistatin for in vitro or animal-model research into TGF-β signaling, myostatin inhibition, and cellular differentiation.
What isoform of follistatin is supplied for research applications?
Laboratory research typically utilizes recombinant Follistatin-344 or Follistatin-315. Follistatin-344 serves as a precursor isoform that is widely studied in cellular expression and myostatin sequestration assays due to its documented stability and affinity profile.
How is the purity of PX1 Research follistatin verified?
PX1 Research verifies every lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish purity (≥98%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify molecular mass and identity. Testing is conducted by independent ISO 17025 accredited laboratories.
What are the acceptable endotoxin limits for in vitro follistatin assays?
For sensitive cell culture and in vitro assays, endotoxin levels should remain below 0.01 EU/μg (or < 0.1 EU/mg). PX1 Research performs Chromogenic LAL testing on every batch to ensure endotoxins do not introduce non-specific inflammatory variables into research models.
How should lyophilized follistatin be reconstituted for cell culture research?
Reconstitute the lyophilized powder using sterile, endotoxin-free water or PBS (pH 7.4). Swirl gently without vortexing. Adding 0.1% BSA or HSA as a carrier protein helps prevent peptide adhesion to plastic containers during stock dilution.
How long can reconstituted follistatin be stored?
Reconstituted liquid solutions stored at 4°C are stable for 7 to 14 days. For extended storage up to 12 months, aliquot the stock into single-use volumes and store at -80°C to eliminate freeze-thaw degradation.
Where does PX1 Research ship follistatin peptide from?
All PX1 Research compounds are manufactured in USA-based facilities and dispatched directly from distribution hubs in California and Arizona. Orders placed Monday through Friday ship same-day.
Is follistatin suitable for human consumption or therapeutic administration?
No. All products offered by PX1 Research, including follistatin peptides, are strictly intended for laboratory research use only (in vitro and preclinical investigation). They are explicitly not for human or veterinary use, therapy, or clinical administration.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.